Featured Research

from universities, journals, and other organizations

World's tiniest drug cabinets could be attached to cancerous cells for long term treatment

Date:
January 14, 2014
Source:
University of Copenhagen
Summary:
As if being sick weren't bad enough, there's also the fear of frequent injections, side effects and overdosing on you medication. Now medical researchers have shown that reservoirs of anti-viral pharmaceuticals could be manufactured to bind specifically to infected tissue such as cancer cells for the slow concentrated delivery of drug treatments.

As if being sick weren't bad enough, there's also the fear of frequent injections, side effects and overdosing on you medication. Now a team of researchers from University of Copenhagen, Department of Chemistry, Nano- science center and the Institut Laue-Langevin (ILL), have shown that reservoirs of anti-viral pharmaceuticals could be manufactured to bind specifically to infected tissue such as cancer cells for the slow concentrated delivery of drug treatments. The new research is published in ACS Macro Letters.

Smaller doses, less injections and fewer side effects

The findings, from Dr Marité Cárdenas (Copenhagen) and Dr Richard Campbell and Dr Erik Watkins (ILL), came as a result of neutron reflectometry studies at a neutron source in Grenoble, France. They could provide a way to reduce dosages and the frequency of injections administered to patients undergoing a wide variety of treatments, as well as minimising side effects of over-dosing.

Fats and branches hold medicine for longer

The attachment of reservoirs of therapeutic drugs to cell membranes for slow diffusion and continuous delivery inside the cells is a major aim in drug R&D. A promising candidate for packaging up and carrying such concoctions of drugs are a group of self-assembled liquid crystalline particles. Composed of fatty molecules known as phospholipids and tree-like macromolecules called dendrimers which have many branches, the particles form spontaneously and have the capacity to soak up and carry large quantities of drug molecules for prolonged diffusion. They are also known for their ability to bind to cellular membranes.

First treatment close to market

The first treatments using such particles are close to market through products incorporating a similar formulation called Cubosomes (cubic phase nanoparticles). Developed and commercialized by Swedish start-up Camarus Ab, its FluidCrystal® nanoparticles promise months of drug delivery from a single injection and the possibility of tuning the delivery to intervals of anything from daily to once monthly. However, a key requirement for optimal application of these formulations is a detailed understanding of how they interact with cellular membranes. This was the focus of work involving a collaboration between Dr Marité Cárdenas (Copenhagen) and Dr Richard Campbell and Dr Erik Watkins (ILL). In this experiment the team used neutrons to analyse the interaction of the liquid crystalline particles with a model cellular membrane whilst varying two parameters:

  • Gravity -- to see how the interaction changed if the aggregates attacked the cell membrane from below as opposed to above
  • Electrostatics -- how the balance between the contrasting positive and negative charges of the aggregate and membrane affect the interaction

Detailed surface information with bouncing electrons

The team utilised a technique known as neutron reflectometry whereby beams of neutrons are skimmed off a surface and the reflectivity measured is used to infer detailed information about the surface, including the thickness, detailed structure and composition of any layers beneath. These experiments were carried out on the FIGARO instrument at the ILL in Grenoble which offers unique reflection up vs. down modes that allowed the team to examine the top and bottom surfaces, alternating the samples on a two hourly basis during a 30 hour sampling period.

Small changes to charge of molecules could have major effects

The interaction of the liquid crystalline particles with the membrane was shown to be driven by the charge on the mode cell wall. Subtle changes in the amount of negative charge on the membrane wall encouraged the tree-like dendrimer molecules to penetrate through allowing the rest of the molecule to bind to the surface, forming an attached reservoir. The sensitivity of the interaction to small changes in charge suggests that simple adjustments to the proportion of charged lipids and macromolecules could optimise this process. In the future this characteristic could also provide a mechanism to focus the treatment at targeted cells such as those infected by cancer which are thought to have a more negative charge density than healthy cells.

"Cancerous cells have an imbalance that gives them a different molecular composition and overall different physical properties to normal healthy cells," explains Dr Cardenas. "Whilst all cells are negative, cancerous cells tend to be more negatively charged than healthy ones due to a different composition of fatty molecules on their surface. This is a property that we believe could be exploited in future research into delivery mechanisms involving the attachment of lamellar liquid crystalline particles. Our next step is to introduce the drug itself into the reservoirs and make sure it can move across the membrane. This work paves the way for cell tests and clinical trials in the future exploiting our methodology"

Gravity important for floating particles

In terms of gravitational affects the analysis also showed that the aggregates interacted preferentially with membranes only when they were located above the sample. Similar effects caused by the different density and buoyancy of solutions is already exploited in some stomach treatments and the researchers would encourage future studies into how gravitational effects could be used to optimise these interactions for drug delivery.

"Of course it's not new that particles in formulations can sink or float, but such dramatically different specific interactions of these nanocarriers with model membranes of different orientations took us completely by surprise" said Dr Campbell. "Very small sample volumes are often used in biomedical investigations so the effects of phase separation cannot be seen. Our findings suggest that laboratory researchers may need to re-evaluate the way in which they examine the effectiveness of newly developed formulations to account for strong gravitational effects."


Story Source:

The above story is based on materials provided by University of Copenhagen. Note: Materials may be edited for content and length.


Journal Reference:

  1. Richard A. Campbell, Erik B. Watkins, Vivien Jagalski, Anna Åkesson-Runnsjö, Marité Cárdenas. Key Factors Regulating the Mass Delivery of Macromolecules to Model Cell Membranes: Gravity and Electrostatics. ACS Macro Letters, 2014; 121 DOI: 10.1021/mz400551h

Cite This Page:

University of Copenhagen. "World's tiniest drug cabinets could be attached to cancerous cells for long term treatment." ScienceDaily. ScienceDaily, 14 January 2014. <www.sciencedaily.com/releases/2014/01/140114203115.htm>.
University of Copenhagen. (2014, January 14). World's tiniest drug cabinets could be attached to cancerous cells for long term treatment. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2014/01/140114203115.htm
University of Copenhagen. "World's tiniest drug cabinets could be attached to cancerous cells for long term treatment." ScienceDaily. www.sciencedaily.com/releases/2014/01/140114203115.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins